ALCHEMIA has entered into a drug discovery agreement with SDP Technology, giving SDP the exclusive rights to develop anti-cancer drugs targeting the enzyme sphingosine kinase 1 using Alchemia’s VAST chemistry.
According to Alchemia, sphingosine kinase 1 plays a central role in cancer by reducing apoptosis (cell death) and promoting cell proliferation and survival. By inhibiting the activity of sphingosine kinase 1, it is possible to arrest tumour growth.
Alchemia says the VAST project has already identified a number of active molecules and shown a strong relationship between their structure and activity.
SDP Technology says the access to Alchemia’s VAST technology has enabled it to take a substantial leap forward in its sphingosine kinase drug discovery and development program.
Add a comment